Alison Schram, MD

Alison M. Schram, MD, of Memorial Sloan Kettering Cancer Center, discusses initial results from the pivotal Phase 2 PYNNACLE trial evaluating rezatapopt, a first-in-class p53 reactivator, in patients with advanced solid tumors harboring a TP53 Y220C mutation.

Dr Schram discusses the significance of the FDA approval of zenocutuzumab for NRG1 fusion–positive NSCLC and pancreatic adenocarcinoma.

Alison Schram, MD, discusses the FDA approval of zenocutuzumab in non–small cell lung cancer and pancreatic cancer harboring NRG1 fusions.

Alison Schram, MD, discusses the efficacy and safety of RLY-4008 in patients with cholangiocarcinoma harboring an FGFR2 fusion or rearrangement.

Alison Schram, MD, discusses the results of the phase 1/2 eNRGy trial, which were presented during the 2021 ASCO Annual Meeting, in NRG1 fusion–positive solid tumors.